AU2009203598B2 - Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide - Google Patents

Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide Download PDF

Info

Publication number
AU2009203598B2
AU2009203598B2 AU2009203598A AU2009203598A AU2009203598B2 AU 2009203598 B2 AU2009203598 B2 AU 2009203598B2 AU 2009203598 A AU2009203598 A AU 2009203598A AU 2009203598 A AU2009203598 A AU 2009203598A AU 2009203598 B2 AU2009203598 B2 AU 2009203598B2
Authority
AU
Australia
Prior art keywords
compound
cancer
compounds
inhibitors
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2009203598A
Other languages
English (en)
Other versions
AU2009203598A1 (en
Inventor
Jennifer R. Foley
Robert Darrin Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40404013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009203598(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2009203598A1 publication Critical patent/AU2009203598A1/en
Assigned to MERCK SHARP & DOHME LTD, MERCK SHARP & DOHME CORPORATION reassignment MERCK SHARP & DOHME LTD Amend patent request/document other than specification (104) Assignors: MERCK & CO., INC., MERCK SHARP & DOHME LTD
Assigned to MERCK SHARP & DOHME LTD, MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME LTD Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK SHARP & DOHME CORPORATION, MERCK SHARP & DOHME LTD
Application granted granted Critical
Publication of AU2009203598B2 publication Critical patent/AU2009203598B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request for Assignment Assignors: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME LTD
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
AU2009203598A 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide Active 2034-01-08 AU2009203598B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1033308P 2008-01-08 2008-01-08
US61/010,333 2008-01-08
PCT/GB2009/000041 WO2009087381A1 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide

Publications (2)

Publication Number Publication Date
AU2009203598A1 AU2009203598A1 (en) 2009-07-16
AU2009203598B2 true AU2009203598B2 (en) 2013-09-26

Family

ID=40404013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009203598A Active 2034-01-08 AU2009203598B2 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide

Country Status (16)

Country Link
US (1) US8436185B2 (enExample)
EP (1) EP2240466B1 (enExample)
JP (1) JP5989965B2 (enExample)
KR (1) KR101653548B1 (enExample)
CN (2) CN101932572A (enExample)
AU (1) AU2009203598B2 (enExample)
BR (1) BRPI0906020A2 (enExample)
CA (1) CA2711491C (enExample)
ES (1) ES2548131T3 (enExample)
FR (1) FR18C1020I2 (enExample)
IL (1) IL206201A (enExample)
MX (1) MX337421B (enExample)
NL (1) NL300938I2 (enExample)
NZ (1) NZ586675A (enExample)
WO (1) WO2009087381A1 (enExample)
ZA (1) ZA201003902B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293897B2 (en) 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
AU2010229147B2 (en) 2009-03-21 2012-07-05 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
SG10201406805RA (en) 2010-02-12 2014-11-27 Pfizer Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
AU2015277212B2 (en) 2014-06-17 2020-07-02 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US10508149B2 (en) 2015-04-01 2019-12-17 Anaptysbio, Inc. Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
CN108291903B (zh) * 2015-09-30 2020-07-28 国立大学法人东北大学 糖尿病性肾病的判定标志物
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
DK3478286T3 (da) 2016-06-29 2024-01-29 Tesaro Inc Fremgangsmåder til behandling af ovariecancer
CN107663190B (zh) * 2016-07-29 2020-06-09 钟桂发 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
WO2018085468A1 (en) 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
MX2019005116A (es) 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
US11926665B2 (en) 2017-01-09 2024-03-12 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
TW201842908A (zh) * 2017-03-27 2018-12-16 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
EP3606524B1 (en) 2017-04-04 2021-12-01 Combiphos Catalysts, Inc. Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
MX2019012793A (es) 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) * 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) * 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
EP3668857B1 (en) 2017-08-14 2023-07-05 Teva Pharmaceuticals International GmbH Processes for the preparation of niraparib and intermediates thereof
WO2019053115A1 (en) * 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
EP3682241B2 (en) * 2017-09-13 2025-09-10 B.R.A.H.M.S GmbH Pct and pro-adm as markers for monitoring antibiotic treatment
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
KR20200067164A (ko) 2017-10-06 2020-06-11 테사로, 인코포레이티드 조합 요법 및 그의 용도
CN111801117A (zh) 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
US20210030735A1 (en) 2018-02-05 2021-02-04 Tesaro, Inc. Pediatric niraparib formulations and pediatric treatment methods
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
TWI853841B (zh) * 2018-10-03 2024-09-01 美商提薩羅有限公司 尼拉帕尼（niraparib）鹽
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2020072860A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
US20220319704A1 (en) 2019-05-06 2022-10-06 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110407704B (zh) * 2019-08-19 2022-05-17 常州沃腾化工科技有限公司 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法
CA3177137A1 (en) 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
EP4472634A1 (en) 2022-02-04 2024-12-11 JANSSEN Pharmaceutica NV Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025027138A1 (en) 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113596A1 (en) * 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008084261A1 (en) * 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004771A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
CA2348374C (en) 1998-10-30 2009-04-07 Lonza Ag Method for producing 4- [(2',5'- diamino-6'- halopyrimidine- 4'-yl)amino]- cyclopent- 2-enylmethanols
KR20010100977A (ko) 1998-11-03 2001-11-14 스타르크, 카르크 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도
AU755694B2 (en) 1998-11-17 2002-12-19 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6508365B1 (en) * 1999-12-28 2003-01-21 Pitney Bowes Inc. Method of removing mail from a mailstream using an incoming mail sorting apparatus
EP1257551B1 (de) 2000-02-01 2007-09-05 Abbott GmbH & Co. KG Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003252315A1 (en) 2002-08-09 2004-02-25 Kyorin Pharmaceutical Co., Ltd. 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE602004017325D1 (de) * 2003-07-21 2008-12-04 Smithkline Beecham Corp (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon
US20050288295A1 (en) * 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
EP1706386A1 (en) 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
KR100876520B1 (ko) 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ES2360232T3 (es) 2005-06-29 2011-06-02 Compumedics Limited Conjunto sensor con puente conductor.
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
ATE461923T1 (de) * 2005-11-15 2010-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
WO2007131016A2 (en) * 2006-05-02 2007-11-15 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US7892667B2 (en) * 2006-09-13 2011-02-22 Altek Corporation Battery security device
JP2008228154A (ja) * 2007-03-15 2008-09-25 Fujitsu Ltd 表示装置，および遠隔操作装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113596A1 (en) * 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008084261A1 (en) * 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Also Published As

Publication number Publication date
CN106008460B (zh) 2022-08-12
CA2711491A1 (en) 2009-07-16
JP5989965B2 (ja) 2016-09-07
ZA201003902B (en) 2011-02-23
IL206201A (en) 2014-07-31
KR101653548B1 (ko) 2016-09-02
JP2011509252A (ja) 2011-03-24
CN101932572A (zh) 2010-12-29
ES2548131T3 (es) 2015-10-14
KR20100114021A (ko) 2010-10-22
EP2240466A1 (en) 2010-10-20
BRPI0906020A2 (pt) 2015-06-30
CN106008460A (zh) 2016-10-12
CA2711491C (en) 2016-03-08
AU2009203598A1 (en) 2009-07-16
MX337421B (es) 2016-03-04
FR18C1020I2 (fr) 2019-06-07
US20100286203A1 (en) 2010-11-11
RU2495035C2 (ru) 2013-10-10
US8436185B2 (en) 2013-05-07
NL300938I2 (nl) 2019-01-08
RU2010133241A (ru) 2012-02-20
IL206201A0 (en) 2010-12-30
FR18C1020I1 (enExample) 2018-07-13
EP2240466B1 (en) 2015-07-29
NZ586675A (en) 2012-04-27
MX2010006593A (es) 2010-12-21
WO2009087381A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
AU2009203598B2 (en) Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide
AU2008204380B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
ES2509115T3 (es) Combinaciones que contienen indazoles sustituidos con amida como inhibidores de poli(ADP-ribosa) polimerasa (PARP)
IL205142A (en) Pyridinone derivatives, their use in curing and the pharmaceutical composition containing them
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

Extension date: 20340108

PC Assignment registered

Owner name: MERCK SHARP & DOHME CORP.

Free format text: FORMER OWNER(S): MERCK SHARP & DOHME CORP.; MERCK SHARP & DOHME LTD

HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.